🇮🇳India

दवा त्रुटि लागत

2 verified sources

Definition

Failure to check drug history/formulary in psych meds leads to interactions and higher costs.

Key Findings

  • Financial Impact: 10-20% reduction in med costs possible; current loss ₹3-7 lakh/clinic/year
  • Frequency: Per prescription without software
  • Root Cause: No centralized med history or formulary access

Why This Matters

The Pitch: Clinics lose ₹3-7 lakh/year to med errors and overprescribing. E-prescribing formularies cut costs by 10-20%.

Affected Stakeholders

Prescribers, Pharmacies

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

नकली दवाओं का खतरा

₹10-20 lakh/year per provider (70% healthcare cost on meds, 5-10% loss to fakes)

ई-फार्मेसी GST अनुपालन

₹1 lakh+ penalty per default + 20-40 hours/month manual ITC reconciliation

प्रिस्क्रिप्शन त्रुटियाँ

₹2-5 lakh/year in rework and compensation per clinic (industry est. 1-2% of revenue from med errors)

उपयोग समीक्षा दस्तावेजीकरण में मैनुअल देरी

30% clinician capacity loss; equivalent to ₹50,000-1,00,000/month revenue per psychiatrist from lost slots

मानसिक क्षमता मूल्यांकन में अस्पष्टता

10-20% error rate in treatment decisions; ₹1-5 lakh per lawsuit or compensation claim

NMHP निगरानी में डेटा देरी

₹40 million allocated to MHIMS with implementation failures; 20-30 days delay in programme funding

Request Deep Analysis

🇮🇳 Be first to access this market's intelligence